Navigation Links
GenTel gets federal grant to develop allergy test

Madison, Wis. - GenTel BioSciences, Inc., a developer of protein chip technologies, has received a $1.2 million Phase II SBIR grant from the National Institutes of Health to develop a test that promises less painful diagnosis of respiratory allergies.

An estimated 50 million Americans suffer from mild to chronic seasonal allergies, and current d......

Full article >>> rovide sizeable amounts of blood and have a slow turnaround time for results, so a small prick of the finger involved in the new test is preferred over both existing methods.

Vodenlich said the company's biochips provide a more qualitative and quantitative way to measure how allergic patients are to certain allergens, which would be a leap forward in allergy diagnosis. GenTel has the all......

Full article >>> A key collaborator on the allergy project is Dr. Robert K. Bush, a professor of medicine at University of Wisconsin-Madison School of Medicine and Public Health. "What our company is all about right now is developing biochip tests that are going to be used in research," Vodenlich said. "The nice thing about the allergy chip is that it will first be used in research and validated by allergists like......

Full article >>>
'"/>

Source:wistechnology.com By Joe Vanden Plas 05/22/06


Related biology technology :

1. GenTel acquires GlaxoSmithKline chip platform
2. New angel capital centered on GenTel agreement with big pharma
3. GenTel licenses next generation cancer research
4. GenTel to distribute cancer research tool
5. Madisons GenTel partners with Taiwan firm
6. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
7. GenTel BioSurfaces launches new assay platform
8. GenTel will sell Dutch firms biomolecule labeling technology
9. Bone Care, GenTel, MyWeather
10. GenTel receives $250,000 state loan
11. GenTel claims $900,000 in federal grants this year for biochip research
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. ... STACS DNA as a Field Application Specialist. , “I am thrilled that Dr. ... STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings a ...
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
Breaking Biology News(10 mins):